Immune-related adverse events are associated with efficacy of immune checkpoint inhibitors (ICIs). We hypothesize that immune-mediated thrombocytopenia could be a biomarker for response to ICIs.
Materials & methods:
This retrospective study included 215 patients with metastatic malignancies treated with ICIs. Patients were stratified by nadir platelet count. Outcomes of interest were progression-free survival and overall survival.
On multivariate analysis, grade 1 thrombocytopenia was positively associated with overall survival compared with patients who did not develop thrombocytopenia (hazard ratio [HR]= 0.28 [95% CI: 0.13–0.60]; p = 0.001), while grade 2–4 thrombocytopenia was not (HR= 0.36 [95% CI: 0.13–1.04]; p = 0.060). There was no association between degree of thrombocytopenia and progression-free survival.
Follow-up studies are warranted to substantiate the predictive significance of thrombocytopenia in patients receiving ICIs.
Assi, H. A., Asch, A. S., Machiorlatti, M., Vesely, S. K., & Ibrahimi, S. (2020). Development of thrombocytopenia is associated with improved survival in patients treated with immunotherapy. Future science OA, 6(7), FSO581. https://doi.org/10.2144/fsoa-2020-0021
Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.
Future Science OA
Population Health and Biostatistics